How the Brainstem Controls Blood Pressure
Scientists have identified a brainstem region called the lateral parafacial area that drives high blood pressure by constricting blood vessels, opening the door to new treatments targeting the neck rather than the brain.
The Silent Killer's Hidden Switch
High blood pressure affects an estimated 1.4 billion adults worldwide, according to the World Health Organization, and remains one of the leading causes of heart attack, stroke, and premature death. For decades, doctors have treated hypertension primarily as a problem of the heart, kidneys, or blood vessels. But a growing body of research points to a surprising culprit: a tiny region deep inside the brainstem.
What Is the Lateral Parafacial Region?
The brainstem sits at the base of the brain, connecting it to the spinal cord. It governs automatic functions we rarely think about — breathing, heart rate, digestion, and blood pressure regulation. Within this ancient structure lies the lateral parafacial region (LPF), an area researchers at the University of Auckland have now linked directly to hypertension.
The LPF's known job is controlling forced exhalation — the abdominal muscle contractions that power a cough, a belly laugh, or heavy breathing during exercise. But the Auckland team, led by Professor Julian Paton of the Manaaki Manawa Centre for Heart Research, discovered that the same neurons also connect to sympathetic nerves that constrict blood vessels, pushing blood pressure upward.
How the Mechanism Works
In healthy individuals, the sympathetic nervous system tightens and relaxes blood vessels as needed — during exercise, stress, or sleep. The brainstem orchestrates much of this activity. The new research, published in Circulation Research, shows that in hypertensive subjects, the lateral parafacial region becomes chronically overactive, sending persistent signals that keep blood vessels constricted.
"We discovered that, in conditions of high blood pressure, the lateral parafacial region is activated and, when our team inactivated this region, blood pressure fell to normal levels," Professor Paton explained.
The upstream trigger is equally revealing. The LPF receives its activation signals from the carotid bodies — tiny clusters of oxygen-sensing cells located in the neck near the carotid artery. In people with hypertension, these sensors become hyperactive, bombarding the brainstem with signals that ramp up sympathetic drive and vessel constriction.
Why This Changes Treatment
Traditional blood pressure medications — ACE inhibitors, beta-blockers, calcium channel blockers — target the cardiovascular system directly. They work for many patients, but roughly one in ten people with hypertension worldwide has their condition adequately controlled, the WHO estimates. Resistant hypertension, where standard drugs fail, affects millions.
The brainstem discovery opens a different approach. Because the carotid bodies sit outside the brain and are accessible to drugs circulating in the bloodstream, researchers can target them without penetrating brain tissue. The Auckland team is investigating repurposing an existing medication — a P2X3 receptor antagonist already approved for chronic cough — to dampen carotid body hyperactivity and, in turn, quiet the overactive brainstem region.
This strategy could prove especially valuable for patients whose hypertension coincides with sleep apnea, a condition in which repeated breathing interruptions at night drive carotid body overactivation and sustained blood pressure elevation.
A Paradigm Shift in Understanding
The research represents a broader shift in how scientists view hypertension. Rather than a disease of the blood vessels alone, high blood pressure may in many cases be a neurological condition — driven by misfiring circuits in the oldest part of the brain. Identifying abnormal abdominal breathing patterns in patients could one day serve as a diagnostic clue pointing to brainstem-driven hypertension.
With nearly half of all hypertensive adults unaware they even have the condition, and treatment control rates stubbornly low across the globe, a new class of therapies targeting the brain-body circuit behind blood pressure regulation could mark a significant advance in the fight against the world's most common cardiovascular disease.
